HIGH POINT, N.C., Dec. 02, 2019 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and Alzheimer’s disease, today announced that it is scheduled to present a general company update at the 31st Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2019 at 10:50 a.m. Eastern Time in New York City. Company management will also be meeting with members of the investment community during one-on-one meetings at the conference.A live webcast of the presentation can be accessed here and will be accessible for 30 days following the presentation at www.vtvtherapeutics.com.About vTv TherapeuticsvTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing oral small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by programs for the treatment of type 1 diabetes, Alzheimer’s disease, and inflammatory disorders. vTv’s development partners are pursuing additional indications in type 2 diabetes, COPD, and genetic mitochondrial diseases.Contacts
Investors:
vTv Therapeutics Inc.
IR@vtvtherapeutics.comor
Bay Street News